Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy.

Eli Lilly shares are trading higher on Monday. The pharmaceutical giant announced a significant European manufacturing expansion.

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a bidding war over the drugmaker Metsera.

A rendering of Eli Lilly's planned plant expansion in Pleasant Prairie. The company is preparing for a next phase on a site to the west in Bristol. The next step after the Mounjaro and Zepbound manufacturer's site plan is approved is a development agreement.

Eli Lilly is expanding its Kenosha County campus with plans to construct six new buildings adjacent to the former Nexus Pharmaceuticals site.

Pharmaceutical maker Eli Lilly (LLY +1.13%) has seen its share price rocket higher by over 500% over the past five years. That stands in stark contrast to a roughly 20% advance fo

Heineken’s Harold van den Broek said beer demand remains soft, Tesla’s Vaibhav Taneja flagged tariff drag, Brian Dykes talked UPS’ liquidity and Lucas Montarce lifted Eli Lilly’s outlook.

Eli Lilly is doubling down on its partnership with Chinese tech outfit XtalPi, striking a new antibody development pact that could net the AI drug discovery shop as much as $345 million. | Eli Lilly is doubling down on its partnership with Chinese tech outfit XtalPi,